A new method for radiochemical separation of arsenic from irradiated germanium oxide.
Radioarsenic labelled radiopharmaceuticals could be a valuable asset to Positron Emission Tomography (PET). In particular, the long half-lives of (72)As (T(1/2)=26 h) and (74)As (T(1/2)=17.8 d) allow to investigate slow physiological or metabolical processes, like the enrichment and distribution of antibodies in tumor tissue. This work describes the direct production of no-carrier-added (nca) arsenic isotopes *As, with *=71, 72, 73, 74 or 77, the reaction to [*As]AsI(3) and its radiochemical separation from the irradiated solid germanium oxide via polystyrene-based solid-phase extraction. The germanium oxide target, irradiated at a cyclotron or a nuclear reactor, is dissolved in concentrated HF and Ge is separated almost quantitatively (99.97%) as [GeF(6)](2-). [*As]AsI(3) is formed by addition of potassium iodide. The radiochemical separation yield for arsenic is >90%. [*As]AsI(3) is a versatile radioarsenic labelling synthon.
Jennewein
M
M
Institute of Nuclear Chemistry, Johannes Gutenberg University of Mainz, Fritz-Strassmann-Weg 2, 55128 Mainz, Germany.
Qaim
S M
SM
Hermanne
A
A
Jahn
M
M
Tsyganov
E
E
Slavine
N
N
Seliounine
S
S
Antich
P A
PA
Kulkarni
P V
PV
Thorpe
P E
PE
Mason
R P
RP
Rösch
F
F
D001151:Arsenic / Q000302:isolation & purification*; D005857:Germanium / Q000737:chemistry*; D006207:Half-Life; D049268:Positron-Emission Tomography / Q000379:methods; D011868:Radioisotopes / Q000302:isolation & purification*; D019275:Radiopharmaceuticals / Q000138:chemical synthesis*
D011868:Radioisotopes; D019275:Radiopharmaceuticals; D005857:Germanium; C040516:germanium oxide; D001151:Arsenic